Background & Aims: Daclatasvir has achieved high sustained virologic response (SVR)
| INTRODUCTION
Direct-acting antiviral (DAA)-only regimens have largely replaced peginterferon-alfa plus ribavirin (pegIFNα/RBV)-containing regimens as standard of care in many countries for chronic hepatitis C virus (HCV) infection. DAA-only regimens are, by comparison, better tolerated and less susceptible to attenuation by factors including cirrhosis, older age and male gender. 1, 2 Daclatasvir (DCV), a pangenotypic non-structural protein-5A (NS5A) inhibitor, exhibits in vitro and clinical activity against HCV genotypes 1-6 and has a favourable safety profile. [3] [4] [5] [6] [7] Multiple studies have evaluated DCV plus other DAAs and/or pegIFNα/RBV. DCV plus sofosbuvir (DCV+SOF) or asunaprevir (DCV+ASV) has achieved high sustained virologic response (SVR) rates in diverse and difficult-to-treat populations. [8] [9] [10] [11] Compared with studies of pegIFNα/RBV-containing regimens, studies of DAA-only regimens have enrolled patients with more advanced disease due to less restrictive clinical and laboratory criteria, and DCV+SOF has achieved high SVR rates in patients with human immunodeficiency virus (HIV) coinfection, decompensated cirrhosis and post-liver transplant recurrence. [12] [13] [14] [15] While favourable outcomes have been reported with short followups, data describing SVR durability, long-term safety and frequency of outcomes of liver failure and hepatocellular carcinoma (HCC), are limited in recipients of DAA-only regimens. Patients with more advanced disease may remain at risk of hepatic disease progression and HCC despite SVR, and require long-term surveillance of their liver disease. 16, 17 This study followed patients treated with DCV-based Methods: Patients enrolled within 6 months of parent study completion or protocol availability at the study sites. The primary objective was durability of SVR at follow-up Week 12 (SVR12). Secondary objectives included analysing HCV sequences in non-responders or responders who relapsed, and characterization of liver disease progression.
Results: Between 24 February 2012 and 17 July 2015, this study enrolled and began following 1503 recipients of daclatasvir-based regimens (follow-up cut-off, 13
October 2015); 60% were male, 18% aged ≥65 years, 87% had genotype-1a (42%) or -1b (45%) infection, and 18% had cirrhosis. Median follow-up from parent study follow-up Week 12 was 111 (range, 11-246) weeks. 1329/1489 evaluable patients were SVR12 responders; 1316/1329 maintained SVR until their latest visit. Twelve responders relapsed by (n = 9) or after (n = 3) parent study follow-up Week 24; one was reinfected. Relapse occurred in 3/842 (0.4%) and 9/487 (2%) responders treated with interferon-free or interferon-containing regimens, respectively. Hepatic disease progression and new hepatocellular carcinoma were diagnosed in 15 and 23 patients, respectively. Among non-responders, emergent non-structural protein-5A (NS5A) and -3 (NS3) substitutions were replaced by wild-type sequences in 27/157 (17%) and 35/47 (74%) patients, respectively.
Conclusions: SVR12 was durable in 99% of recipients of daclatasvir-based regimens.
Hepatic disease progression and new hepatocellular carcinoma were infrequent. Emergent NS5A substitutions persisted longer than NS3 substitutions among non-responders.
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Key points
• This large, long-term follow-up study investigated efficacy and safety among 1503 patients with chronic HCV infection and a diverse range of disease backgrounds treated with daclatasvir-based regimens
• Among responders, SVR12 durability was 99%
(n = 1316/1329), with most relapses occurring within 24 weeks of parent study EOT (n = 9) rather than during this long-term follow-up study (n = 3)
• Hepatic disease progression or new HCC, while infrequent, was more common among patients treated in studies of DAA-only regimens (n = 24/36), which could enroll patients with more advanced liver disease
• Among non-responders, emergent NS5A substitutions were more persistent than NS3 substitutions.
regimens for chronic HCV infection in phase 2 or 3 studies with the aim of evaluating long-term efficacy and safety, including type and frequency of hepatic disease progression.
| METHODS

| Study design
This 144-week, observational, multicenter study enrolled patients within 6 months of parent study completion or protocol availability at the clinical site (NCT01492504). The study protocol was approved by the institutional review board or independent ethics committee at each site (Table S1 ). Study conduct adhered to local laws and regulatory requirements, and was in accordance with Good Clinical Practice as defined by the International Conference on Harmonization and the principles of the Declaration of Helsinki. All patients provided written informed consent.
| Patients
Eligible patients were aged ≥18 years and had received ≥1 DCV dose for chronic HCV. Enrolment was permitted regardless of cirrhosis status and virologic response. Patients in control arms could participate until unblinded treatment information was released for the parent study protocol, at which time they could choose to continue follow-up in this study. Patients retreated for HCV infection post-parent study completion were ineligible.
| Study objectives
The primary objective was to determine SVR12 durability (time to loss of SVR achieved at parent study follow-up Week 12; HCV-RNA ≥lower limit of quantification [LLOQ] ). Secondary objectives included analysing HCV sequences in non-responders or responders who relapsed, and characterizing liver disease progression. 
| Assessments
| Statistical analysis
Enrolled patients had signed informed consent forms and were assigned patient identification numbers. Eligible patients had enrolled and met the eligibility criteria (primary analysis population).
Efficacy and liver disease progression endpoints were evaluated per parent treatment. Exploratory analyses included parent study baseline, end-of-treatment (EOT) and follow-up data. Categorical variables were summarized with counts and percentages, continuous variables and changes from baseline with univariate statistics.
Unless specified otherwise, longitudinal efficacy analyses used pre-defined intervals from parent study EOT, and endpoints were presented at 24-week intervals using the last available measurement up to and including the analysis time-point. Patients without measurements were excluded for that interval. Laboratory data were summarized with US values and units using measurements taken centrally or locally, graded using the Division of AIDS Table   for Grading the Severity of Adult and Pediatric Adverse Events. For hepatic disease progression, HCC, cirrhosis, all-cause and liverrelated mortality, imputed onset dates were used to calculate event durations. (Table 1) ; DCV+pegIFNα/RBV recipients may have received 24 weeks of additional pegIFNα/ RBV. Patients were followed until 13 October 2015, at which point follow-up had been completed by 201 patients; 157 discontinued due to withdrawn consent (n = 52), death (n = 9) or other reason (n = 19), 34 were lost to follow-up, and 43 no longer met study criteria due to HCV retreatment (n = 41) or incarceration (n = 2) (Table S3 ).
| RESULTS
| Patient disposition
| Baseline characteristics
Most patients were male (60%), infected with genotype-1a (42%) or -1b (45%), and received DAA-only regimens (59%); 18% had cirrhosis and 3% were liver transplant recipients ( Table 2) . Of 269 cirrhotic patients, 183 (68%) and 86 (32%) received DAA-only or IFN-containing regimens, respectively. All liver transplant recipients received DAA-only regimens.
Of 1503 patients, 1489 (99%) were evaluable; 1329 (88%)
were SVR12 responders (median age, 56 years), 160 (11%) were non-responders (median age, 57 years). Male and cirrhotic patients were proportionally similar between responders (n = 792/1329, 60%; n = 238/1329, 18%) and non-responders (n = 100/160, 63%; n = 24/160, 15%). However, genotype-1a-infected patients and recipients of IFN-containing regimens were proportionally larger among non-responders (n = 88/160, 55%; n = 114/160, 71%) vs responders (n = 537/1329, 40%; n = 487/1329, 37%).
Median (range) follow-up from parent study follow-up Week 12
was 111 (11-246) weeks; 44 One responder, treated for genotype-1a infection, was re-infected with genotype-3a during this study.
| Hepatic disease progression
Prior to parent study EOT, the medical histories reported hepatic disease progression in 88 recipients of DAA-only (n = 75) or IFNcontaining (n = 13) regimens, HCC in 10 recipients of DAA-only regimens, and cirrhosis in 261 recipients of DAA-only (n = 181) or IFN-containing (n = 80) regimens (Table 3) and non-responders (n = 3/160, 2%).
| Safety
Eleven deaths, all unrelated to parent treatment, were reported (Table 5 ). Three recipients of DCV+ASV (n = 2) or DCV+pegIFNα/ RBV (n = 1) died from liver disease. Eight patients died from events (14) 72 (27) 44 (22) 42 ( No SAEs related to parent treatment were reported. (Table 6 ; Figure 4C ,D). The most commonly replaced NS3 substitutions among non-responders with genotype-1a and -1b infection were R155K (n = 9) and D168V (n = 11), respectively; median (range) times to replacement were 53 (21-62) and 24 weeks, respectively.
| Clinical resistance
| DISCUSSION
The emergence of DAAs has resulted in diverse and difficult-to-treat HCV populations achieving high SVR rates. Patients who achieve SVR are generally considered to be cured and at reduced risk of HCV-related complications; [18] [19] [20] [21] however, those with more advanced disease remain at risk of hepatic disease progression and HCC, and require long-term surveillance of their liver disease. 17, 22 This study, the largest conducted in the context of DAA-only reg- cirrhotic DAA-treated patients vs 47% of untreated patients, and 2.2% of liver transplant recipients. 31 Similarly, a retrospective Japanese study in a similar population found that early tumour recurrence was no higher after treatment with DAAs compared with IFN or control agents. 32 As well as HCC recurrence, a retrospective cohort study of data from the Veterans Affairs HCV Clinical Case Registry identified elevated risks of new HCC in patients aged ≥65 years, or with cirrhosis, diabetes or genotype-3 infection at the time of SVR. 17 Such characteristics, while detrimental to pegIFNα/RBV treatment outcome, are readily overcome with DAA-based regimens; persistence of such characteristics, however, may contribute to new HCC incidence several years post-SVR. 16, 17 During this study, hepatic disease progression (n = 15, 1%) or cirrhosis (n = 21, 1%) diagnoses were infrequent and evenly distributed among responders and non-responders, despite 269 and 39 patients being cirrhotic or liver transplant recipients, respectively, upon entry.
Percentage of patients
New HCC (n = 23, 2%) was equally infrequent and evenly distributed among responders (n = 20/1329, 2%) and non-responders (n = 3/160, 2%). All diagnoses were non-recurrent, although only 10 patients with prior HCC were enrolled; this population was excluded by the majority of parent studies. Nonetheless, the 2% incidence is low and comparable with incidences in similar populations of the aforementioned Italian study (3%) and a retrospective study of Japanese responders treated with DAAs (2.6%) or pegIFN/RBV (2.3%). 30, 33 Among these 23 patients,
18 received DAA-only regimens, most of whom were male (n = 12), cirrhotic (n = 10) or aged ≥65 years (n = 12) upon entry; all were treated for genotype-1 infection, another HCC risk factor (Table S4) . 34, 35 Furthermore, platelet counts were low in many of these patients, Consequently, these studies could enroll patients with severe portal hypertension, which is considered an independent HCC predictor. America, as well as Russia and Israel, and was the first DAA regimen approved in Japan, and is currently the only DAA regimen approved in China.
Co-formulated DCV+ASV+BCV was recently approved in Japan and has proven effective against genotype-1b NS5A polymorphisms known to attenuate response to dual-drug NS5A inhibitor combinations.
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In summary, the results of this large, unique follow-up study indicate that SVR achieved with DCV-based regimens is durable in the long-term, with no safety sequelae related to parent treatment.
Hepatic disease progression was infrequent, and no increased risk for new or recurrent HCC was observed in patients with more advanced disease treated with DAA-only regimens. T A B L E 6 Replacement of emergent NS5A and NS3 substitutions since parent study EOT among non-responders Pertaining to emergent substitutions that were replaced. e Pertaining to emergent substitutions that were not replaced. f Also detected using next-generation sequencing (sensitivity, ≥1%). g Excludes two patients initially designated as having genotype-1b infection, but later shown using population-based sequencing of the NS5A region to have genotype-1a infection.
F I G U R E 4 Replacement of emergent NS5A and NS3 substitutions with wild-type sequences since parent study EOT among non-responders. Time to replacement of emergent NS5A substitutions among patients infected with (A) genotype-1a, or (B) genotype-1b; time to replacement of emergent NS3 substitutions among patients infected with (C) genotype-1a, or (D) genotype-1b.
a One DCV+pegIFNα/RBV recipient infected with genotype-1b is excluded due to replacement of their emergent NS5A substitution beyond the study's observational window
